Bio4t2 is overcoming the major barriers in targeting solid tumors with CAR-T.
PrismCore and
Bio-Engine are showing promising clinical results in our first CAR-T product that targets overexpressed self-antigens on solid tumors.
Bi-CAR-T is on track for clinical application.
